XRTXXORTX TherapeuticsXRTX info
$1.73info-1.14%24h
Global rank35215
Market cap$3.46M
Change 7d42.98%
YTD Performance-24.78%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    XORTX Therapeutics (XRTX) Stock Overview

    XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.

    XRTX Stock Information

    Symbol
    XRTX
    Address
    3710 – 33rd Street NWAlberta Beach, AB T2L 2M1Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.xortx.com
    Country
    🇨🇦 Canada
    Phone Number
    403 455 7727

    XORTX Therapeutics (XRTX) Price Chart

    -
    Value:-

    XORTX Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.73
    N/A
    Market Cap
    $3.46M
    N/A
    Shares Outstanding
    2.00M
    N/A
    Employees
    3.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org